News items related to: News
-
Brazil: 10 years of a Compulsory License on HIV drug Efavirenz
Symposium in Curitiba highlights the need for a collective fight to make medicines affordable. When governments are unreceptive, it is...
-
Patients demand AbbVie’s price bubble is burst – key HIV drug out of reach
AbbVie’s monopoly has hiked prices – it’s time to burst the bubble and get prices back down to earth. Activists...
-
Malaysia paves the way for compulsory licensing on hepatitis C medicines
Historic decision will cure more hepatitis C patients – and other countries can follow suit. Today, 20 September 2017, Malaysia’s...
-
Online access: Training course on reducing barriers to medicines in Africa
Making intellectual property issues easier to understand, to increase access to medicines – and you can apply now! An online...
-
Tackling the hepatitis C epidemic in Malaysia
With new, revolutionary, drugs available, why isn’t everyone getting the cure? An estimated 454,000 people are living with hepatitis C...
-
An important step towards affordable TAF in Ukraine
Gilead adds TAF, a drug used in HIV and Hepatitis B treatment, to the Medicines Patent Pool for Ukraine. It...
-
IAS 2017: Closing ceremony exposes Gilead Sciences
Conference funders, Gilead Sciences, named and shamed for its “insatiable greed” Yesterday, the 9th International AIDS Conference on HIV Science...
-
A victory for ITPC-MENA : Bristol-Myers Squibb extends its voluntary license on atazanavir to Egypt
During the 9th International AIDS Conference (23-26 July 2017), Bristol-Myers Squibb (BMS) and the Medicines Patent Pool (MPP) announced the...
-
HIV activists denounce ViiV for denying 3.5 million people access to optimal treatment
Today, Monday, 24 July 2017, during the 9th International AIDS Conference on HIV Science in Paris (IAS 2017), HIV treatment...
-
Intellectual Property Group opposes a resolution which would restrict access to medicines in Brazil
Our partner in Brazil highlights the facts in a debate full of confusion. Last month, the Working Group on Intellectual...
-
Brazil: Open letter insists that pharmaceuticals’ interests must NOT be prioritized over public health
The Working Group on Intellectual Property responds to what it sees as ‘an attack on the rights of the Brazilian...
-
Victory: Gilead forced to withdraw Truvada® patent application in Argentina
Gilead prevented from obtaining an illegitimate monopoly at the expense of people’s health. Activists in Argentina, including our partner...